X

Trial Profile

A Phase II Trial to Evaluate AE-M in Combination with Checkpoint Inhibitors for the Treatment of Melanoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AE-M (Primary)
Indications Malignant melanoma
Focus Therapeutic Use

Most Recent Events

22 Jan 2020 New trial record
16 Jan 2020 According to a Generex Biotechnology Corporation media release, the company expects to achieve the public spin-out of NGIO in the first quarter of calendar 2020.Following funding of the newly-public NGIO, the company plans to conduct two phase II trials (CT profiles 317166 and 317166).Both of these trials are being planned with two leading oncology research institutions, and additional announcements will be forthcoming regarding these clinical collaborations.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com